JP2009082138A5 - - Google Patents

Download PDF

Info

Publication number
JP2009082138A5
JP2009082138A5 JP2008301520A JP2008301520A JP2009082138A5 JP 2009082138 A5 JP2009082138 A5 JP 2009082138A5 JP 2008301520 A JP2008301520 A JP 2008301520A JP 2008301520 A JP2008301520 A JP 2008301520A JP 2009082138 A5 JP2009082138 A5 JP 2009082138A5
Authority
JP
Japan
Prior art keywords
temperature
medium
hmba
cell line
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008301520A
Other languages
English (en)
Other versions
JP2009082138A (ja
JP4414472B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009082138A publication Critical patent/JP2009082138A/ja
Publication of JP2009082138A5 publication Critical patent/JP2009082138A5/ja
Application granted granted Critical
Publication of JP4414472B2 publication Critical patent/JP4414472B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (15)

  1. 組換えポリペプチドを産生する方法であって
    哺乳動物細胞株を培地中で35℃〜38℃の温度で培養してから、29℃〜36℃の第ニの温度にシフトさせ;
    培養培地にヘキサメチレン・ビスアセトアミド(HMBA)を添加する
    ことを含んでなり;
    ここにおいて、哺乳動物細胞株が、組換えポリペプチドを産生するように遺伝子操作されており、そして
    第一の温度から第二の温度へのシフトの後、数時間ないし数日後に、HMBAが添加される、
    前記方法。
  2. 酪酸の塩を、第一の温度から第二の温度へのシフトから、数時間ないし数日後に添加す、請求項1の方法。
  3. 培地中の酪酸の塩の濃度が、0.1mM〜2mMである、請求項2の方法
  4. 培地中のHMBAの濃度が、0.1ミリモル〜20ミリモルである、請求項1ないし3のいずれか1項の方法。
  5. 培地中のHMBAの濃度が、0.5ミリモル〜10ミリモルである、請求項4の方法。
  6. 培地中のHMBAの濃度が、0.1ミリモル〜5ミリモルである、請求項4の方法。
  7. 培地中に、キサンチン愉導体を、第一の温度から第二の温度へのシフトから、数時間ないし数日後に添加する、請求項1ないし6のいずれか1項の方法。
  8. キサンチン誘導体がカフェインであり、そして、カフェインが0.01ないし3.0mMの濃度で添加される、請求項7の方法。
  9. 培地が血清不含である、請求項1ないし8のいずれか1項の方法。
  10. 細胞株が、CHO細胞株あるいはハイブリドーマ細胞株である、請求項1ないし9のいずれか1項の方法。
  11. 組換えポリペプチドが、RANK:Fc、II型インターロイキン−1受容体、TNFR:Fc、CD40リガンド、TRAIL、flt3リガンド、IL−4受容体、G−CSF、エリスロポエチン、および抗体からなる群より選択される、請求項1ないし10のいずれか1項の方法。
  12. さらに、培地から組換えポリペプチドを回収することを含む、請求項1ないし11のいずれか1項の方法。
  13. ポリペプチドを産生する方法であって
    ポリペプチドを発現可能な哺乳動物細胞株を35℃ないし38℃の温度で培養し、そして、次いで
    血清不含の培地中、少なくとも5日間、29℃ないし36℃の温度で細胞を培養する、
    ことを含んでなり、
    ここにおいて、HMBA及び酪酸の塩を、0.5ないし10mM HMBA及び0.1ないし2mM 酪酸塩の濃度で、温度シフトの後、数時間ないし数日後に添加する、
    前記方法。
  14. ポリペプチドが、RANK:Fc、II型インターロイキン−1受容体、TNFR:Fc、CD40リガンド、TRAIL、flt3リガンド、IL−4受容体、G−CSF、エリスロポエチン、および抗体からなる群より選択される、請求項13の方法。
  15. ポリペプチドを産生するように遺伝子操作されているCHO細胞株、及びHMBAを含んでなる血清不含の産生培地、を含んでなる細胞培養物であって、
    ここにおいて、培養物は、35℃ないし38℃の第一の温度で培養されており、そして、次いで、29℃ないし36℃の第二の温度にシフトして少なくとも5日間培養されている、並びに、
    、第一の温度から第二の温度へのシフトの後、数時間ないし数日後にHMBAが添加される、
    前記細胞培養物。
JP2008301520A 2002-03-27 2008-11-26 ポリペプチド産生を増加させる方法 Expired - Lifetime JP4414472B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36824802P 2002-03-27 2002-03-27
US36824602P 2002-03-27 2002-03-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003580502A Division JP2005521401A (ja) 2002-03-27 2003-03-27 ポリペプチド産生を増加させる方法

Publications (3)

Publication Number Publication Date
JP2009082138A JP2009082138A (ja) 2009-04-23
JP2009082138A5 true JP2009082138A5 (ja) 2009-06-04
JP4414472B2 JP4414472B2 (ja) 2010-02-10

Family

ID=28678222

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003580502A Pending JP2005521401A (ja) 2002-03-27 2003-03-27 ポリペプチド産生を増加させる方法
JP2008024395A Expired - Lifetime JP4414466B2 (ja) 2002-03-27 2008-02-04 ポリペプチド産生を増加させる方法
JP2008301520A Expired - Lifetime JP4414472B2 (ja) 2002-03-27 2008-11-26 ポリペプチド産生を増加させる方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2003580502A Pending JP2005521401A (ja) 2002-03-27 2003-03-27 ポリペプチド産生を増加させる方法
JP2008024395A Expired - Lifetime JP4414466B2 (ja) 2002-03-27 2008-02-04 ポリペプチド産生を増加させる方法

Country Status (9)

Country Link
US (2) US6872549B2 (ja)
EP (1) EP1497444B1 (ja)
JP (3) JP2005521401A (ja)
AU (1) AU2003220529B2 (ja)
CA (1) CA2480121C (ja)
ES (1) ES2557741T3 (ja)
MX (1) MXPA04009381A (ja)
PL (1) PL376821A1 (ja)
WO (1) WO2003083066A2 (ja)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
WO2003083066A2 (en) * 2002-03-27 2003-10-09 Immunex Corporation Methods for increasing polypeptide production
WO2004046340A2 (en) * 2002-11-14 2004-06-03 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
JP2007525176A (ja) * 2003-04-25 2007-09-06 イミュネックス・コーポレーション 組換えタンパク質発現の誘導剤
EP1656148A4 (en) * 2003-08-21 2011-07-20 Duchesnay Inc SUPPLEMENT OF MICRONUTRIENT
JP4520987B2 (ja) * 2003-08-21 2010-08-11 デュシェネ インク チャイルドプルーフ微量栄養素サプリメント
WO2005063813A2 (en) * 2003-12-23 2005-07-14 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
WO2007049567A1 (ja) * 2005-10-24 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. 物質の製造方法
SI1969007T1 (sl) 2005-12-20 2014-03-31 Bristol-Myers Squibb Company Sestavki in postopki za izdelavo sestavka
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP2623609B1 (en) * 2006-02-10 2017-01-04 Life Technologies Corporation Labeling and detection of post translationally modified proteins
CA2661175C (en) * 2006-08-14 2014-08-05 Biocontrol Systems, Inc. Method for detecting pathogens depending on incubation temperature variation
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CA2910619A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
AU2008232732A1 (en) * 2007-03-28 2008-10-09 Medarex, Inc. Methods of gene amplification and expression
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
WO2009114693A1 (en) * 2008-03-12 2009-09-17 Wyeth Method for identifying cells suitable for large-scale production of recombinant proteins
KR20140015152A (ko) * 2009-12-02 2014-02-06 악셀레론 파마 인코포레이티드 Fc 융합 단백질의 혈청 반감기를 증가시키는 조성물들 및 방법들
CN103080221B (zh) 2010-09-30 2015-11-25 大金工业株式会社 防熔滴剂以及树脂组合物
WO2012091124A1 (ja) * 2010-12-28 2012-07-05 中外製薬株式会社 動物細胞の培養方法
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
IL310968A (en) 2011-07-01 2024-04-01 Amgen Inc Mammalian cell culture
EP2653548A1 (de) 2012-04-17 2013-10-23 Greenovation Biotech GmbH Verfahren zur Erhöhung der Sekretion rekombinanter Proteine
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
EP2970888A4 (en) * 2013-03-15 2017-04-12 Theocorp Holding Co., LLC Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
KR102190790B1 (ko) * 2018-10-19 2020-12-15 주식회사 프로젠 변형된 egf 단백질의 생산 방법
US11339197B2 (en) 2017-10-23 2022-05-24 Progen Co., Ltd. Modified EGF protein, production method therefor, and use thereof
WO2022140389A1 (en) 2020-12-22 2022-06-30 Amgen Inc. Cell culture method

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3824286A (en) 1970-07-07 1974-07-16 Lever Brothers Ltd Preparation of polyacetylalkylene diamines
EP0005476B1 (de) 1978-05-17 1981-12-30 Dr. Karl Thomae GmbH Verfahren zur Herstellung von Humaninterferon
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
US4357422A (en) 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
US4416986A (en) 1981-01-16 1983-11-22 Merck & Co., Inc. Methods of producing HBsAg
US4473647A (en) 1981-02-27 1984-09-25 Amf Inc. Tissue culture medium
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4992472A (en) 1987-06-16 1991-02-12 The United States Of America As Represented By The Department Of Health And Human Services Chemical differentiating agents
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5330744A (en) 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
ZA899421B (en) 1988-12-14 1990-09-26 Merrell Dow Pharma Method of potentiating natural killer cell activity
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US20010010922A1 (en) 1994-06-09 2001-08-02 Riccardo Dalla-Favera Cloning and uses of the genetic locus bcl-6
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
ATE310813T1 (de) 1995-06-29 2005-12-15 Immunex Corp Apoptosis induzierendes cytokin
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1998028010A2 (en) 1996-12-24 1998-07-02 Hyal Pharmaceutical Corporation Use of moieties for binding to hyaluronan and icam-1
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999032605A1 (en) 1997-12-19 1999-07-01 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
JP2002526109A (ja) 1998-10-02 2002-08-20 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ アポトーシス誘導物質と方法
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6506598B1 (en) 1999-04-26 2003-01-14 Genentech, Inc. Cell culture process
WO2001027299A1 (en) 1999-10-13 2001-04-19 Immunex Corporation Vectors and methods for recombinant protein expression
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
AU2001259432B2 (en) 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
WO2003083066A2 (en) * 2002-03-27 2003-10-09 Immunex Corporation Methods for increasing polypeptide production

Similar Documents

Publication Publication Date Title
JP2009082138A5 (ja)
Ho et al. Engineering strategies for improving the CO2 fixation and carbohydrate productivity of Scenedesmus obliquus CNW-N used for bioethanol fermentation
JP2019004912A5 (ja)
CA2480121A1 (en) Methods for increasing polypeptide production
Crosby et al. Extreme thermophiles as emerging metabolic engineering platforms
BR112012027282A2 (pt) meio de cultura de células aperfeiçoado
Qiao et al. Engineering cyanobacteria as cell factories for direct trehalose production from CO2
JP2007502114A5 (ja)
JP2015521848A5 (ja)
JP2013545491A5 (ja)
BR112012009828A8 (pt) método para a produção de uma imunoglobulina glicosilada
RU2014128987A (ru) Быстрый способ клонирования и экспрессии сегментов гена родственной вариабельной области антитела
JP6961713B2 (ja) タガトース生産用組成物及びこれを用いたタガトースの製造方法
RU2010119233A (ru) Новые гидрогеназы, выделенные из thermococcus spp., гены, кодирующие эти гидрогеназы, и способы продуцирования водорода с использованием микроорганизмов, содержащих указанные гены
JP2016513478A5 (ja)
AU2019400151B2 (en) Recombinant Escherichia coli system, construction method thereof, and usage in synthesis of α-1,2-fucosylated oligosaccharide
RU2015144020A (ru) Среды для культивирования клеток и способы получения антител
TW201446966A (zh) 新穎o-磷絲胺酸輸出蛋白及其製造方法
US20240279699A1 (en) ENZYME COMPOSITION FOR PREPARING Beta-NICOTINAMIDE MONONUCLEOTIDE, AND APPLICATION THEREOF
Pembroke et al. Metabolic engineering of the model photoautotrophic cyanobacterium synechocystis for ethanol production: Optimization strategies and challenges
CN109706104B (zh) sll0528基因在提高集胞藻PCC6803乙醇耐受性中的应用
KR101903553B1 (ko) 중쇄 아미노카르복시산의 생산 방법
JP2009100702A5 (ja)
CN104845961A (zh) 产1,3-二羟基丙酮重组基因工程菌的固定化及应用
KR102157781B1 (ko) 디카르복시산 생산을 위한 미생물 및 이를 이용한 디카르복시산 생산방법